Discovery of altered pharmacokinetics of CGP 15 210 G in poor hydroxylators of debrisoquine during early drug development.
作者信息
Gleiter C H, Aichele G, Nilsson E, Hengen N, Antonin K H, Bieck P R
出版信息
Br J Clin Pharmacol. 1985 Jul;20(1):81-4. doi: 10.1111/j.1365-2125.1985.tb02802.x.
Abstract
The pharmacokinetics of CGP 15 210 G, a new 5-HT uptake inhibitor in poor and extensive metabolisers of debrisoquine, give indirect evidence of an association between its metabolism and polymorphic hydroxylation of the debrisoquine type.
摘要
相似文献
1
Discovery of altered pharmacokinetics of CGP 15 210 G in poor hydroxylators of debrisoquine during early drug development.
Br J Clin Pharmacol. 1985 Jul;20(1):81-4. doi: 10.1111/j.1365-2125.1985.tb02802.x.
2
The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.
Br J Clin Pharmacol. 1984 Jun;17(6):679-85. doi: 10.1111/j.1365-2125.1984.tb02403.x.
3
Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism.
Clin Pharmacol Ther. 1984 Oct;36(4):515-9. doi: 10.1038/clpt.1984.212.
4
Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings.
Clin Pharmacol Ther. 1989 Jul;46(1):78-81. doi: 10.1038/clpt.1989.109.
5
The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.
Clin Pharmacokinet. 1986 Jan-Feb;11(1):1-17. doi: 10.2165/00003088-198611010-00001.
6
Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation.
Br J Clin Pharmacol. 1989 Dec;28(6):639-45. doi: 10.1111/j.1365-2125.1989.tb03556.x.
7
Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.
Br J Clin Pharmacol. 1982 Aug;14(2):301-3. doi: 10.1111/j.1365-2125.1982.tb01982.x.
8
E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation.
Clin Pharmacol Ther. 1981 Aug;30(2):189-93. doi: 10.1038/clpt.1981.147.
9
Polymorphism of debrisoquine hydroxylation among Finns and Lapps.
Br J Clin Pharmacol. 1988 Nov;26(5):601-3. doi: 10.1111/j.1365-2125.1988.tb05301.x.
10
The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine.
Eur J Clin Pharmacol. 1987;33(1):59-65. doi: 10.1007/BF00610381.
引用本文的文献
1
Role of cytochrome P4502D6 in the metabolism of brofaromine. A new selective MAO-A inhibitor.
Eur J Clin Pharmacol. 1993;45(3):265-9. doi: 10.1007/BF00315394.
2
Clinical significance of the sparteine/debrisoquine oxidation polymorphism.
Eur J Clin Pharmacol. 1989;36(6):537-47. doi: 10.1007/BF00637732.
3
Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics.
Clin Pharmacokinet. 1990 Mar;18(3):220-39. doi: 10.2165/00003088-199018030-00004.
本文引用的文献
1
A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.
J Med Genet. 1980 Apr;17(2):102-5. doi: 10.1136/jmg.17.2.102.
2
[Drug hydroxylation disorders (debrisoquin type) in a random sample of the Swiss population].
Schweiz Med Wochenschr. 1982 Jul 24;112(30):1061-7.
3
Protecting poor metabolizers, a group at high risk of adverse drug reactions.
Lancet. 1983 Jun 18;1(8338):1388. doi: 10.1016/s0140-6736(83)92172-4.
4
Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection.
J Chromatogr. 1977 Mar 11;133(1):161-6. doi: 10.1016/s0021-9673(00)89216-x.
5
Polymorphisms of oxidation at carbon centers of drugs and their clinical significance.
Drug Metab Rev. 1979;9(2):301-17. doi: 10.3109/03602537908993896.
6
Polymorphic hydroxylation of Debrisoquine in man.
Lancet. 1977 Sep 17;2(8038):584-6. doi: 10.1016/s0140-6736(77)91430-1.
Zotero 插件